The pivotal role of the immune system in the initiation and progression of heart failure (HF) is supported by extensive literature.1,2 These findings have resulted in several studies on the effects of immunomodulatory therapies in HF, mostly focusing on tumour necrosis factor-α (TNF-α). Here, TNF is linked to hydrops fetalis.